Alleviation of the drug-resistant phenotype in idarubicin and cytosine arabinoside double-resistant acute myeloid leukemia cells by indomethacin

We developed an acute myeloid leukemia cell line that is resistant to treatment with a combination of idarubicin and cytosine arabinoside by chronic exposure for more than 3 months

Ju Song

2014

Scholarcy highlights

  • Chemotherapy has been extensively used for the treatment of patients with acute myeloid leukemia, and one of the recent treatment strategies is based on a combination
  • We developed an AML cell line that was resistant to treatment with a combination of idarubicin and cytosine arabinoside by subjecting the cells to chronic exposure to these compounds for >3 months
  • The results of this study indicate that indomethacin enhances the anticancer drug-induced apoptosis of drug-resistant AML-2/IDAC cells
  • AML-2/IDAC cells were cultured in the absence or presence of indomethacin alone or in combination with antileukemic drugs for 48 h
  • The results of this study indicate that indomethacin can alleviate the drug-resistant phenotype in AML cells, and that this occurs by activation of a chemotherapeutic drug-induced apoptotic pathway and suppression of some ATP-binding cassette transporters, such as ABCA3 and MRP1

Need more features? Save interactive summary cards to your Scholarcy Library.